Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y.C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B.C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A.

doi:10.1016/S0959-8049(22)01000-0

YUHSpace

BROWSE

0 488

Cited 0 times in

Cited 2 times in

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

Authors: Besse, B. ; Springfeld, C. ; Baik, C. ; Hervieu, A. ; Solomon, B. ; Moreno, V. ; Bazhenova, L. ; Goto, K. ; Kim, Y.C. ; Lu, S. ; Sun, M. ; Trone, D. ; Thamake, S. ; Cho, B.C. ; de Langen, A. ; Popat, S. ; Wolf, J. ; Moro-Sibilot, D. ; Fang, J. ; Drilon, A.